1073186-85-2

Basic information

• Product Name: 5-[4-(3,5-di-tert-butyl-4-hydroxy-phenylsulfanyl)-piperidine-1-sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid meglumine salt
• Synonyms: 5-[4-(3,5-di-tert-butyl-4-hydroxy-phenylsulfanyl)-piperidine-1-sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid meglumine salt
• CAS NO: 1073186-85-2
• Molecular Weight: 703.919
• Mol File: 1073186-85-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5-[4-(3,5-di-tert-butyl-4-hydroxy-phenylsulfanyl)-piperidine-1-sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid meglumine salt(CAS DataBase Reference)
• NIST Chemistry Reference: 5-[4-(3,5-di-tert-butyl-4-hydroxy-phenylsulfanyl)-piperidine-1-sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid meglumine salt(1073186-85-2)
• EPA Substance Registry System: 5-[4-(3,5-di-tert-butyl-4-hydroxy-phenylsulfanyl)-piperidine-1-sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid meglumine salt(1073186-85-2)

Safety Data

• Hazardous Substances Data: 1073186-85-2(Hazardous Substances Data)

Upstream product

• 141699-59-4 1-(tert-butoxycarbonyl)piperidin-4-yl methanesulfonate 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 1073186-96-5 2,6-di-tert-butyl-4-(piperidin-4-ylsulfanyl)-phenol hydrochloride 
• 1073186-99-8 5-[4-(3,5-di-tert-butyl-4-hydroxy-phenylsulfanyl)-piperidine-1-sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester 
• 1073186-95-4 4-(3,5-di-tert-butyl-4-hydroxy-phenylsulfanyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 1073186-97-6 2,6-di-tert-butyl-4-(piperidin-4-ylsulfanyl)-phenol 
• 306936-53-8 methyl 5-(chlorosulfonyl)-1-methyl-1H-pyrrole-2-carboxylate 
• 1073186-72-7 5-[4-(3,5-di-tert-butyl-4-hydroxy-phenylsulfanyl)-piperidine-1-sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid 
• 6284-40-8 1-deoxy-1-(methylamino)-D-glucitol 

Relevant articles and documents

SULFONAMIDE CONTAINING COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS

Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of an inflammatory condition, in particular asthma. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof: wherein: X and Y are independently selected from-CH2-or-CH2-CH2;Z is seleceted from S(O)m or Se(O)m and m is 0, 1 or 2; R1 is optionally substituted heteroaryl or heterocyclic; R2 is selected from the group consisting of hydrogen, C1 -C6 straight alkyl, and C1 -C6 branched alkyl, wherein all may be optionally substituted; and R3 and R4 are alkyl.